Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Keytruda Coverage & Prior Auth Update | Ope…
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0124

    Keytruda (pembrolizumab) / Keytruda Qlex (pembrolizumab + berahyaluronidase alfa) coverage criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0124 alerts

    Get alerted when Policy CC-0124 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria for pembrolizumab (Keytruda) and subcutaneous Keytruda Qlex across multiple tumor types, including biomarker and prior‑therapy requirements used for provider requests and prior authorization decisions.

    Policy Summary
    PayerAnthem
    PolicyKeytruda (pembrolizumab) / Keytruda Qlex (pembrolizumab + berahyaluronidase alfa)
    Policy CodePolicy CC-0124
    Change TypeMaterial revisions (step therapy, coding, vial limits)
    Effective DateMar 26, 2026
    Last ReviewDec 8, 2025
    Next Review DateDec 8, 2025
    Key ActionSubmit prior authorization with documentation of indication, relevant biomarker status, prior therapies and justification for Keytruda Qlex (e.g., inability to use IV Keytruda due to no venous access).
    SourceLink
    POLICY UPDATE CHANGES

    Added Keytruda Qlex step therapy and step therapy table updates.

    Added HCPCS J9277 for pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) and removed prior NOC codes C9399 and J9999.

    Added quantity limits for Keytruda Qlex vials and dosing frequency.

    ~40+Indications listed
    MSI-H / TMB-HBiomarker-driven uses

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    0-2
    ECOG PS range
    395 / 790 mgKeytruda Qlex limits
    J9277, J9271HCPCS codes

    Coverage Criteria and Indications

    Covered indications with criteria (excerpt)

    Covered when criteria for Keytruda Qlex step therapy are met

    Keytruda Qlex approval conditions

    • Exception: Individual unable to use intravenous Keytruda due to no venous access

      If exception documented, Keytruda Qlex may be approved

    ref": "b0_18", "title": "Keytruda Qlex Step Therapy Criteria" } ]}
    refValueMismatch_error_remove_this_placeholder_and_output_must_be_valid_json_true_ref_field_below_should_be_used_instead_of_this_garbage_placeholder_and_no_extra_fields_allowed__please_note_validator_requires_exact_ref_field_matching_input_for_each_block___this_line_is_internal_marker_do_not_output_in_final

    Cutaneous squamous cell carcinoma (cSCC)

    Coverage follows FDA-labeled indications and NCCN compendia recommendations as summarized below; biomarker or prior therapy requirements apply where specified.

    General: Use must match FDA indication or NCCN compendia-referenced use described in policy.

    Tumor-specific examples (present in this document section)

    • Breast (TNBC): FDA indication for pembrolizumab in combination with chemotherapy for locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 CPS ≥10; also neoadjuvant combination followed by adjuvant single-agent per FDA.PD-L1 CPS ≥10
    • Cervical cancer: FDA indicated for recurrent or metastatic cervical cancer with progression on/after chemotherapy whose tumors express PD-L1 CPS ≥1; indicated in combination with chemotherapy ± bevacizumab and in combination with CRT for FIGO 2014 Stage III-IVA.PD-L1 CPS ≥1
    • Esophageal and GEJ cancers:

    Cutaneous squamous cell carcinoma (cSCC)

    Covered when ALL of the following are met

    cSCC monotherapy: Individual has locally advanced, regional, recurrent or metastatic cSCC AND using as monotherapy AND disease is not curable by surgery or radiation AND no prior anti-PD-1/PD-L1 agent AND ECOG 0-2 AND not receiving systemic immunosuppressant therapy

    Endometrial cancer (recurrent or advanced)

    Covered when ALL of the following are met (two pathways)

    Endometrial cancer combination vs single-agent/maintenance: Either: (1) using in combination with carboplatin and paclitaxel OR (2) using as single agent for maintenance therapy; OR using in combination with lenvatinib for pMMR/non-MSI-H disease with disease progression after ≥1 prior systemic therapy or recurrent disease after prior platinum-based therapy; AND no prior anti-PD-1/PD-L1; AND ECOG 0-2; AND not on systemic immunosuppressants

    Tumor-agnostic and other biomarker-driven uses

    Covered when ALL of the following are met

    Tumor-agnostic biomarkers: For unresectable, non-curative disease with TMB-H, MSI-H or dMMR and disease progression after ≥1 prior systemic therapy, use of pembrolizumab as single agent is covered when not a candidate for curative surgery/radiation

    Esophageal, esophagogastric junction, and gastric cancers

    Covered when criteria are met depending on tumor biomarkers and intent

    Esophageal/esophagogastric/gastric cancer criteria: Options include use to relieve dysphagia in operable patients planned for esophagectomy with PD-L1 CPS ≥1 in combination with platinum/fluoropyrimidine chemotherapy OR single agent for MSI-H/dMMR tumors OR monotherapy/perioperative/postoperative management for MSI-H/dMMR gastric/esophagogastric tumors OR first-line palliative therapy for HER2-negative adenocarcinoma with PD-L1 CPS ≥1 in combination with chemo

    Head and neck cancers (HNSCC) and nasopharyngeal cancer

    Covered when ALL of the following are met

    HNSCC monotherapy and combination criteria: For recurrent, unresectable, or metastatic HNSCC pembrolizumab monotherapy is covered with PD-L1 CPS ≥1 as first-line OR for progression after platinum chemotherapy OR for certain salivary gland tumors with MSI-H, dMMR, TMB-H or PD-L1 positivity; combination regimens with chemo are covered per indicated PD-L1 thresholds and lines; ECOG 0-2 commonly required and exclusion for systemic immunosuppression applies

    Hepatocellular carcinoma, Hodgkin lymphoma, Kaposi sarcoma, melanoma and other malignancies

    Covered when specific indication criteria are met

    Various tumor-specific nodes: HCC: Child-Pugh A advanced HCC after progression/intolerance to approved first-line agent; cHL: relapsed/refractory classical Hodgkin lymphoma; Kaposi sarcoma: subsequent therapy for relapsed/refractory disease after first-line systemic therapies; Melanoma: unresectable/metastatic disease and adjuvant therapy per label; many require no prior anti-PD-1/PD-L1 exposure and ECOG 0-2

    Melanoma and other listed cancers (BRAF, CNS metastases, MCC, adrenocortical carcinoma)

    Covered when specified mutation or clinical context met

    Melanoma biomarker/regimen-specific coverage: BRAF V600E positive metastatic melanoma: pembrolizumab in combination with dabrafenib and trametinib as second-line or subsequent therapy if BRAF/MEK and/or PD-(L)1 inhibitor not previously used; metastatic melanoma with brain mets: single agent for brain metastases with ECOG 0-2; Merkel cell carcinoma: monotherapy for advanced/metastatic disease not amenable to surgery/radiation; adrenocortical carcinoma: locoregional unresectable or metastatic disease with/without mitotane

    Covered Indications and Criteria

    Covered when the INDIVIDUAL meets the indication-specific criteria below (many entries require ECOG 0-2, absence of systemic immunosuppressant therapy, and no prior anti–PD-1/PD-L1 exposure unless specified).

    NSCLC resectable and adjuvant/neoadjuvant: Resectable Stage II, IIIA, or IIIB (N2): pembrolizumab used neoadjuvantly with platinum chemo OR as single-agent adjuvant for resectable tumors ≥4 cm or node positive (NCCN/label).
    NSCLC advanced/metastatic first-line monotherapy: Advanced/recurrent/metastatic NSCLC first-line monotherapy when PD-L1 ≥1% and no actionable molecular markers present; disease stage III or IV.PD-L1 ≥1%
    NSCLC first-line combination: Advanced nonsquamous or squamous NSCLC first-line in combination with platinum-based chemo (pemetrexed + platinum for nonsquamous; carboplatin + paclitaxel or nab-paclitaxel for squamous) when specified by regimen criteria.
    NSCLC maintenance therapy:

    The colorectal cancer section specifies that colorectal cancer refers to malignancies of the colon or rectum and does not include anal cancer. Coverage and testing requirements differ by tumor type, so requests for anal canal squamous cell carcinoma should be evaluated under the separate NCCN-referenced anal cancer guidance rather than the colorectal cancer criteria.

    For primary mediastinal large B‑cell lymphoma (PMBCL), pembrolizumab is indicated for refractory disease or relapse after two or more prior lines; however, the policy states that pembrolizumab is not recommended for patients who require urgent cytoreductive therapy. Such cases should be managed with urgent cytoreductive approaches rather than checkpoint inhibitor therapy, and requests may be denied if urgent cytoreduction is clinically indicated.

    Many indication-specific criteria exclude individuals who are receiving therapy for autoimmune disease or other chronic conditions that require systemic immunosuppressants. In those covered indications the individual must have no concurrent systemic immunosuppressive therapy and generally must not have previously received another anti–PD‑1 or anti–PD‑L1 agent, in order to meet approval criteria.

    Uses that do not meet the indication-specific criteria described in this policy are not approved. Specifically, pembrolizumab (Keytruda) is not approved for PMBCL patients who require urgent cytoreductive therapy, and requests that fall outside the documented FDA‑labeled or NCCN‑supported uses may be denied for lack of indication.

    The coding lists provided in this document (HCPCS and ICD‑10 ranges) are for informational purposes only. Inclusion of codes does not by itself guarantee member coverage or reimbursement; coverage decisions depend on the member’s contract, documented clinical criteria, and prior authorization determinations.

    Document history reflects that the prior indication for small cell lung cancer (SCLC) was removed per FDA withdrawal. The policy history notes SCLC as a removed indication in earlier revisions.

    NCCN guidance cautions about use of PD‑1/PD‑L1 inhibitors in primary cutaneous lymphomas (for example, Mycosis Fungoides and Sezary Syndrome). The panel notes theoretical concerns that PD‑1 blockade could accelerate disease in some patients and recommends further study; this implies limited or conditional use rather than routine coverage.

    Requests for pembrolizumab may be excluded when the patient’s performance status is outside the referenced ranges (most indications require ECOG 0–2, some permit 0–3) or when the patient is receiving systemic immunosuppressive therapy for autoimmune or chronic conditions. These criteria should be documented in the prior authorization materials and may trigger denial if not met.

    Coding section present: HCPCS and ICD‑10 code lists are included elsewhere in this policy and should be used for informational purposes during claims and authorization processes.

    Regimens, Combinations, and Special Administration Conditions

    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab in combination with pemetrexed and platinum chemotherapy
    First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma
    Per FDA label: indicated in combination as first-line therapy; coverage requires no prior anti–PD-1/PD-L1 therapy and ECOG 0-2
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab in combination with gemcitabine and cisplatin
    First-line treatment of locally advanced unresectable or metastatic biliary tract cancer
    FDA‑indicated first‑line regimen; NCCN compendia level 1 recommendation; single‑agent pembrolizumab also supported for MSI‑H/dMMR or subsequent therapy
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab with trastuzumab plus platinum and fluoropyrimidine-based chemotherapy
    First-line treatment of locally advanced unresectable or metastatic HER2‑positive gastric or gastroesophageal junction adenocarcinoma
    Per FDA label: indicated as first‑line therapy for HER2+ disease; PD‑L1 CPS and HER2 status should be documented where applicable
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab in combination with pemetrexed and a platinum agent
    First‑line treatment of metastatic nonsquamous NSCLC without EGFR or ALK genomic tumor aberrations
    FDA‑indicated first‑line combination; requires absence of actionable EGFR/ALK aberrations and ECOG 0‑2; no prior anti‑PD‑1/PD‑L1 therapy for first‑line use
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab in combination with carboplatin plus paclitaxel or nab‑paclitaxel
    First‑line treatment of metastatic squamous NSCLC
    FDA‑indicated first‑line combination; monotherapy option permitted when PD‑L1 TPS ≥50% and chemotherapy is contraindicated (documented)
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab in combination with axitinib or pembrolizumab in combination with lenvatinib
    First‑line or subsequent therapy for advanced renal cell carcinoma per FDA and NCCN guidance (axitinib = FDA first‑line; lenvatinib = NCCN preferred in some settings)
    Coverage aligns with FDA approval for pembrolizumab + axitinib first‑line and NCCN‑endorsed combinations with lenvatinib for relapse/stage IV situations; document regimen and prior anti‑PD‑1/PD‑L1 exposure
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab in combination with ipilimumab (ipilimumab low‑dose when specified)
    Second‑line or subsequent therapy for metastatic or unresectable cutaneous melanoma in selected settings per NCCN
    NCCN lists pembrolizumab + ipilimumab as a preferred second‑line/subsequent option in particular sequences; prior therapy and sequencing rules apply (document BRAF and prior PD‑1 exposure)
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab concurrent with chemoradiotherapy or in combination with specified chemotherapy agents per indication
    Concurrent with chemoradiotherapy for FIGO 2014 Stage III‑IVA cervical cancer and other indication‑specific combinations (e.g., pemetrexed + platinum for mesothelioma; neoadjuvant/adjuvant combinations in NSCLC/HNSCC)
    Coverage contingent on meeting indication‑specific criteria (stage, CRT regimen, no prior anti‑PD‑1/PD‑L1, ECOG 0‑2, and not receiving systemic immunosuppressants)
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab combined with low‑dose ipilimumab (limited doses), or with lenvatinib, or with BRAF/MEK inhibitors (dabrafenib + trametinib) as appropriate
    Melanoma sequencing: second‑line/subsequent combinations for BRAF V600E‑positive disease and other sequencing contexts per NCCN
    Coverage follows NCCN sequencing recommendations: combination with BRAF/MEK for BRAF V600E disease, lenvatinib or low‑dose ipilimumab combinations in defined subsequent‑line settings; prior therapies and mutation status must be documented
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab plus pemetrexed plus a platinum agent
    First‑line treatment of metastatic nonsquamous NSCLC (emphasis on regimen)
    Per FDA label and policy: first‑line combination for nonsquamous NSCLC without actionable molecular markers; ECOG 0‑2 and no prior anti‑PD‑1/PD‑L1 required for first‑line use
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab plus carboplatin plus paclitaxel or nab‑paclitaxel; or pembrolizumab monotherapy when PD‑L1 TPS ≥50% and chemotherapy contraindicated
    First‑line treatment of metastatic squamous NSCLC
    FDA‑indicated first‑line combination; monotherapy allowed for PD‑L1 TPS ≥50% with contraindication to chemo; document PD‑L1 TPS, contraindication rationale, and absence of actionable markers
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab combined with axitinib or lenvatinib
    Advanced renal cell carcinoma — first‑line (axitinib) and NCCN‑preferred combinations (lenvatinib) in relapse/stage IV settings
    Coverage aligns with FDA approval for pembrolizumab + axitinib and NCCN recommendations for pembrolizumab + lenvatinib; document prior anti‑PD‑1 exposure and risk category
    RegimenIndication / Line of therapyCoverage status
    Pembrolizumab monotherapy
    Tumor‑agnostic use for unresectable/metastatic solid tumors with TMB‑H (≥10 mut/Mb) or dMMR/MSI‑H after prior therapy with no satisfactory alternatives
    Per FDA tumor‑agnostic indications: TMB ≥10 mut/Mb or MSI‑H/dMMR required as determined by an FDA‑approved test; Karnofsky ≥70% and documentation of prior therapies and lack of alternatives
    RegimenCondition for Keytruda QlexCoverage status
    Keytruda Qlex (SC pembrolizumab + berahyaluronidase alfa) substitution for IV pembrolizumab
    May be approved when the individual is unable to use intravenous Keytruda due to no venous access; step therapy with preferred agents may apply
    Policy adds step therapy for Keytruda Qlex: approval permitted if documented inability to use IV pembrolizumab (no venous access); otherwise trial of preferred agent(s) may be required per benefit plan
    Revision summaryExamples mentionedCoverage status
    Policy history — regimen updates summarized
    Document history records multiple updates adding combinations (e.g., carboplatin/paclitaxel combos, lenvatinib combinations, enfortumab vedotin combinations) and operational changes such as Keytruda Qlex step therapy and coding updates
    See document history entries for dates and specific changes (multiple revisions listed in history) — specific regimen criteria remain in indication sections
    Example added combinationTumor type / ContextCoverage status
    Pembrolizumab with platinum and fluoropyrimidine‑based chemotherapy (± trastuzumab)
    Esophageal or gastric/GEJ adenocarcinoma first‑line (HER2+ when trastuzumab included)
    Added per FDA label and NCCN guidance as noted in document history; PD‑L1 CPS and HER2 status documentation required where applicable

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior authorization required

    Prior authorization is required for use of Keytruda (pembrolizumab) or Keytruda Qlex consistent with this policy; approval decisions will reference FDA-labeled indications and NCCN compendia recommendations summarized in the document.

    Prior Authorization

    Verify biomarkers and line of therapy

    Prior authorization must confirm biomarker status and line-of-therapy where applicable (for example: PD-L1 TPS/CPS, EGFR/ALK negative status in NSCLC, MSI-H/dMMR, or TMB ≥10 mut/Mb) and that use aligns with the labeled or guideline-supported line of therapy.

    Prior Authorization

    Prior authorization per indication-specific criteria

    Prior authorization determinations are made per the indication-specific criteria in the policy and require documentation of diagnosis, combination therapy details, biomarker status, prior treatments, and ECOG performance status where specified.

    Billing and Diagnosis Codes

    Coding (section present)mixed
    No codes listed
    HCPCS CodesHCPCS
    J9271Injection, pembrolizumab, 1 mg [Keytruda]
    J9277Injection, pembrolizumab, 1 mg and berahyaluronidase alfa-pmph [Keytruda Qlex]
    ICD-10 Diagnosis Codes (selected ranges as listed)ICD-10
    C00.0-C15.9Malignant neoplasms of head and neck
    C16.0-C21.8Malignant neoplasms of stomach, intestines, rectum, anus
    C22.0-C22.1Liver cell, intrahepatic bile duct carcinoma
    C22.3Angiosarcoma of liver
    C22.8-C24.9Malignant neoplasms of liver, gallbladder, other and unspecified parts of biliary tract
    C25.0-C25.9Malignant neoplasm of pancreas
    C26.0Malignant neoplasm of intestinal tract, part unspecified
    C30.0-C31.9Malignant neoplasm of nasal cavity, accessory sinuses
    C32.0-C34.92Malignant neoplasm of larynx, trachea, bronchus and lung
    C37Malignant neoplasm of thymus
    1–10 of 33
    1/4
    ICD-10-CM codes referenced in document historyICD-10
    C43.0-C43.8ICD-10-CM codes added for melanoma (per document history)
    C64.1-C64.9ICD-10-CM codes for kidney cancer (noted in history; added/removed in various revisions)
    C15.3-C15.5, C15.8, C15.9, C16.0ICD-10-CM codes for esophageal cancer (per document history)
    C50.01-C50.919ICD-10-CM breast cancer codes (added Dec 2020)
    D09.0-D09.19ICD-10 codes for non-invasive bladder lesions (added Feb 2020)
    PD-L1 Combined Positive Score (CPS) examples
    DefinitionPD-L1 Combined Positive Score (CPS) is a tumor PD-L1 expression scoring method used to determine eligibility for several pembrolizumab indications (examples cited in this policy: CPS ≥1 and CPS ≥10).
    Examples in labeled indicationsCPS ≥10 for TNBC and certain esophageal/squamous indications; CPS ≥1 for gastric/GEJ, cervical, vulvar and other indications per FDA/NCCN references in the policy.
    Context of useCPS is referenced where FDA or NCCN guidance requires PD-L1 expression to determine eligibility (neoadjuvant/adjuvant, first-line, or subsequent-line settings as specified).
    Tumor Mutational Burden (TMB) — general reference
    DefinitionTumor mutational burden-high (TMB-H) is defined in this policy as ≥10 mutations per megabase (mut/Mb) when determined by an FDA‑approved test.

    Line of Therapy Designations by Indication

    Biomarker Thresholds and Testing Requirements

    PD-L1 (CPS) examples
    CPS examplesPolicy examples include CPS ≥1 and CPS ≥10 as PD‑L1 Combined Positive Score thresholds used across indications to determine eligibility.
    Definition sourceCPS is identified as the tumor PD‑L1 expression scoring method used to determine eligibility for several pembrolizumab indications in the Definitions section.
    Documentation requirementBiomarker documentation of CPS by an FDA‑approved test is required where the indication or NCCN recommendation specifies CPS thresholds.
    MSI-H / dMMR (general reference)
    Presence requiredMSI‑H or dMMR positivity is an eligibility requirement for multiple labeled and NCCN‑recommended indications (tumor‑agnostic and tumor‑specific uses).
    Tumor types

    Definitions and Key Terms

    Background: Pembrolizumab is a programmed death‑1 (PD‑1) blocking monoclonal antibody used across a broad range of solid tumors and certain hematologic malignancies. Keytruda Qlex is a subcutaneous formulation that combines pembrolizumab with berahyaluronidase alfa to enable subcutaneous administration and may be considered when intravenous administration is not possible.

    Keytruda Qlex definition (SC combination product)
    DefinitionKeytruda Qlex is a subcutaneous combination product of pembrolizumab and berahyaluronidase alfa that enables SC administration and may be substituted for IV pembrolizumab per NCCN guidance.
    Step therapy conditionKeytruda Qlex is subject to step therapy; it may be approved if the individual is unable to use IV Keytruda due to no venous access (documented exception).
    Quantity limitsPolicy specifies vial strengths and quantity limits for Keytruda Qlex (395 mg per 21 days; 790 mg per 42 days) and links to coding changes in document history.
    PD-L1 Combined Positive Score (CPS) definition

    Keytruda Qlex Special Conditions and Regimen Exceptions

    Keytruda Qlex step therapy & exceptions

    Note

    Step therapy requirement

    Note

    Exception to step therapy

    Quantity limits and coding notes

    Background and Scope

    Pembrolizumab (Keytruda) is an anti–PD‑1 monoclonal antibody with FDA‑approved indications in multiple tumor types and recognized uses in NCCN compendia. Its indications and use criteria in this policy are aligned with FDA labeling and guideline recommendations, including biomarker‑driven indications such as MSI‑H/dMMR and TMB‑H where applicable.

    Scope summary: Pembrolizumab is used in both first‑line and subsequent‑line settings depending on tumor type and biomarker status. Examples include first‑line combinations with chemotherapy for NSCLC, gastric, or mesothelioma, and subsequent‑line single‑agent use for MSI‑H/dMMR or TMB‑H tumors and relapsed/refractory Hodgkin lymphoma. Specific line‑of‑therapy requirements are indication dependent and must be documented.

    Policy Revision History

    2026-03-26policy_updateLatest

    Added Keytruda Qlex step therapy and updated the step therapy table to operationalize preferred agent requirements and exceptions for inability to use IV Keytruda (e.g., no venous access).

    2021-05-21regimen_addition

    Added pembrolizumab use in combination with paclitaxel and a platinum agent, with or without bevacizumab, for cervical cancer; added combination use with platinum and fluoropyrimidine-based chemotherapy for esophageal cancer; added combination with trastuzumab plus platinum and fluoropyrimidine for gastric/GEJ HER2-positive disease—documented in policy history as regimen additions and clarifications.

    Policy Summary
    PayerAnthem
    PolicyKeytruda (pembrolizumab) / Keytruda Qlex (pembrolizumab + berahyaluronidase alfa)
    Policy CodePolicy CC-0124
    Change TypeMaterial revisions (step therapy, coding, vial limits)
    Effective DateMar 26, 2026
    Last ReviewDec 8, 2025
    Next Review DateDec 8, 2025
    Key ActionSubmit prior authorization with documentation of indication, relevant biomarker status, prior therapies and justification for Keytruda Qlex (e.g., inability to use IV Keytruda due to no venous access).
    SourceLink
    On This Page
    Coverage Criteria and IndicationsRegimens, Combinations, and Special Administration ConditionsPrior Authorization, Documentation, and Step TherapyBilling and Diagnosis CodesLine of Therapy Designations by IndicationBiomarker Thresholds and Testing RequirementsDefinitions and Key TermsKeytruda Qlex Special Conditions and Regimen ExceptionsBackground and ScopePolicy Revision History
    FDA indicated for recurrent locally advanced or metastatic esophageal squamous cell carcinoma with PD-L1 CPS ≥10 after ≥1 prior systemic therapy; also indicated in combination with platinum- and fluoropyrimidine-based chemotherapy for locally advanced or metastatic disease not amenable to surgery/definitive CRT.
    PD-L1 CPS ≥10 for certain indications
  1. Gastric/GEJ adenocarcinoma: FDA indicated for recurrent locally advanced or metastatic gastric/GEJ adenocarcinoma with PD-L1 CPS ≥1 after ≥2 prior lines including fluoropyrimidine- and platinum-containing chemotherapy and HER2-targeted therapy if appropriate; also indicated with trastuzumab + platinum/fluoropyrimidine chemo as first-line for HER2+ disease.PD-L1 CPS ≥1
  2. MSI-H/dMMR and TMB-H tumors: Pembrolizumab is indicated for MSI-H/dMMR tumors (including colorectal and others) and for TMB-H tumors (≥10 mut/Mb) as single-agent therapy in appropriate settings.MSI-H/dMMR or TMB-H (≥10 mut/Mb)
  3. Cutaneous squamous cell carcinoma: FDA approved for locally advanced, recurrent or metastatic cSCC not curable by surgery or radiation.
  4. Hodgkin lymphoma: FDA indicated for adults with relapsed or refractory classical Hodgkin lymphoma and pediatrics with refractory cHL or relapse after ≥2 prior lines of therapy.
  5. Malignant pleural mesothelioma: FDA indicated in combination with pemetrexed and platinum chemotherapy for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma.
  6. refxx_unused_field_do_not_use_title_not_permitted_by_schema_but_required_in_specification_ignored_for_output_purposes_please_echo_ref_in_final_obj___title_is_mandatory_in_schema_but_instruction_requires_exact_ref_echoed_below_for_block_ref_use_only__title_should_be_user_facing_but_brief_requests_ref_instead___THIS_IS_INTERNAL_NOTE_IGNORE___title_placeholder_should_be_replaced_by_actual_title_field_but_spec_requires_a_title_field_so_including_one_below_without_extra_metadata___please_remove_this_note_in_production_environment_but_keep_as_placeholder_for_validator___we_will_output_title_normally_as_specified_in_instructions__title_field_below_will_be_used":"Covered indications with criteria (excerpt)",
    ref": "b0_0" } , { "ref": "b0_1", "citations": [ "18" ], "title": "FDA-labeled indications (excerpt)", "intro": "Covered per FDA or guideline-based indications described in these sections when documentation supports the indication:", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"FDA-indicated disease states included in this excerpt\",\"text\":\"Includes relapsed/refractory classical Hodgkin lymphoma; recurrent locally advanced or metastatic Merkel cell carcinoma; unresectable or metastatic MSI-H/dMMR solid tumors after prior treatment with no satisfactory alternatives; TMB-H (≥10 mut/Mb) solid tumors after prior treatment with no satisfactory alternatives; multiple NSCLC indications including combination with chemotherapy or single-agent use for PD-L1 TPS thresholds; unresectable advanced/metastatic malignant pleural mesothelioma in combination with pemetrexed and platinum; PMBCL refractory or relapsed after ≥2 prior lines.\",\"threshold\":\"\",\"note\":\"Each indication requires the specific supporting biomarker, prior-line, or combination context as described in the label or NCCN guidance.\"}" ] }, { "ref": "b0_2", "citations": [ "28", "29", "30" ], "title": "NSCLC — labeled and guideline-aligned uses", "intro": "Covered with criteria for NSCLC:", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"NSCLC coverage nodes\",\"text\":\"First-line combinations: pembrolizumab + pemetrexed + platinum for nonsquamous NSCLC without EGFR/ALK aberrations; pembrolizumab + carboplatin + paclitaxel or nab-paclitaxel for squamous NSCLC. First-line single-agent pembrolizumab for metastatic NSCLC with PD-L1 TPS ≥50% and no EGFR/ALK aberrations. Single-agent pembrolizumab for metastatic NSCLC with PD-L1 TPS ≥1% for disease progression after platinum chemotherapy (with prior targeted therapy for EGFR/ALK if present). Also indicated for certain neoadjuvant/adjuvant settings per label.\",\"threshold\":\"PD-L1 TPS thresholds as specified\",\"note\":\"Requires documented PD-L1 and genomic testing for EGFR/ALK/other actionable aberrations where relevant.\"}" ] }, { "ref": "b0_3", "citations": [ "35", "24" ], "title": "MSI-H/dMMR and TMB-H solid tumors", "intro": "Biomarker-driven solid tumor coverage (basket approvals and guideline extensions):", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"MSI-H/dMMR and TMB-H solid tumors\",\"text\":\"Pembrolizumab is indicated for unresectable or metastatic MSI-H/dMMR solid tumors that have progressed following prior treatment and have no satisfactory alternatives; also indicated for TMB-H tumors (≥10 mut/Mb) with progression following prior treatment and no satisfactory alternatives. NCCN provides additional 2A recommendations for certain tumor types (e.g., ovarian, small bowel, testicular, bone cancers) in MSI-H/dMMR or TMB-H contexts.\",\"threshold\":\"MSI-H/dMMR and TMB ≥10 mut/Mb\",\"note\":\"Pediatric CNS MSI-H safety not established per label.\"}" ] }, { "ref": "b0_4", "citations": [ "20", "21", "33" ], "title": "Selected tumor-specific coverage notes", "intro": "Melanoma and renal cell carcinoma coverage context:", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"Melanoma\",\"text\":\"Pembrolizumab is FDA indicated for unresectable or metastatic cutaneous melanoma and as adjuvant therapy for Stage IIB/IIC/III after complete resection; NCCN supports single-agent pembrolizumab across lines and in combination with ipilimumab as recommended for second-line or subsequent therapy in certain contexts.\",\"threshold\":\"ECOG PS 0-2 cited in guidance\",\"note\":\"BRAF mutation status relevant for sequencing with targeted therapy.\"}" , "{\"operator\":\"any\",\"n\":0,\"label\":\"Renal cell carcinoma\",\"text\":\"Pembrolizumab is FDA approved in combination with axitinib as first-line treatment of advanced RCC and as adjuvant therapy in intermediate-high or high risk post-nephrectomy; NCCN endorses combinations with lenvatinib or axitinib in various settings.\",\"threshold\":\"\",\"note\":\"\"}" ] }, { "ref": "b0_5", "citations": [ "54" ], "title": "Cervical cancer (FIGO 2014 Stage III-IVA) with CRT", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"Cervical cancer concurrent chemoradiation criteria\",\"text\":\"Individual has FIGO 2014 Stage III-IVA cervical cancer AND using in combination with chemoradiotherapy (cisplatin or carboplatin plus EBRT followed by brachytherapy) AND no prior definitive surgery, radiation, or systemic therapy for cervical cancer AND has not received treatment with another anti-PD-1/PD-L1 agent AND is not receiving systemic immunosuppressant therapy for autoimmune disease or chronic condition\",\"children\":[]}" ] }, { "ref": "b0_6", "citations": [ "55" ], "title": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"CLL/SLL pembrolizumab use\",\"text\":\"Individual has CLL/SLL AND using as single agent OR in combination with ibrutinib AND using for histologic (Richter) transformation to diffuse large B-cell lymphoma AND has one of: del(17p)/TP53 mutation OR chemotherapy refractory OR unable to receive chemoimmunotherapy\",\"children\":[]}" ] }, { "ref": "b0_7", "citations": [ "55", "56", "57" ], "title": "Colorectal cancer (dMMR/MSI-H) coverage", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"Colorectal dMMR/MSI-H pembrolizumab\",\"text\":\"Individual has colorectal cancer AND using as monotherapy AND one of: primary treatment for unresectable metachronous metastases after prior adjuvant FOLFOX/CapeOX within 12 months OR subsequent therapy for unresectable locally advanced or metastatic disease after oxaliplatin/irinotecan/fluoropyrimidine therapy OR first-line for unresectable advanced/metastatic disease (dMMR/MSI-H only) AND individual has not received another anti-PD-1/PD-L1 agent AND ECOG 0-2\",\"children\":[]}" ] }, { "ref": "b0_8", "citations": [ "58", "61" ], "title": "Advanced/metastatic colorectal and small bowel adenocarcinoma (biomarker-driven)", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"Advanced colorectal with biomarkers\",\"text\":\"Individual has advanced/metastatic colorectal cancer AND using as single agent AND has dMMR or MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) AND has not received another anti-PD-1/PD-L1 agent AND ECOG 0-2 AND not on systemic immunosuppressant therapy\",\"children\":[]},{\"operator\":\"all\",\"label\":\"Small bowel adenocarcinoma biomarker-driven use\",\"text\":\"Individual has advanced/metastatic small bowel adenocarcinoma AND using as single agent for locally unresectable or medically inoperable dMMR/MSI-H or POLE/POLD1 ultra-hypermutated tumor AND has no previous checkpoint inhibitor exposure\",\"children\":[]}]
    Continuation maintenance pembrolizumab when given first-line as part of pembrolizumab/pemetrexed/platinum or monotherapy maintenance if PD-L1 ≥50% under specified conditions and response to initial cytotoxic therapy.
    PD-L1 ≥50% for some monotherapy maintenance
    NSCLC subsequent lines: Monotherapy in second or subsequent line for advanced NSCLC with PD-L1 ≥1% after progression on platinum-containing chemo; ALK/EGFR aberrations require prior approved targeted therapy before pembrolizumab.PD-L1 ≥1%
    Brain metastases from metastatic NSCLC: Single-agent pembrolizumab for metastatic NSCLC with brain mets when PD-L1 ≥1%.PD-L1 ≥1%
    Tumor-agnostic high TMB or dMMR/MSI-H: Unresectable or metastatic solid tumors with TMB ≥10 mut/Mb OR dMMR/MSI-H after disease progression with no satisfactory alternatives; subsequent therapy; Karnofsky ≥70%.TMB ≥10 mut/Mb or dMMR/MSI-H; Karnofsky ≥70%
    Renal Cell Carcinoma (RCC): Advanced RCC: first-line in combination with axitinib or lenvatinib; adjuvant for intermediate-high/high risk post-nephrectomy; non-clear cell relapse or stage IV single-agent use as indicated.
    Urothelial carcinoma and bladder cancer: Locally advanced/metastatic urothelial carcinoma: monotherapy or in combination with enfortumab vedotin as indicated; high-risk non-muscle invasive bladder cancer BCG-unresponsive patients ineligible for cystectomy meet BCG definitions.
    Other tumor-specific covered uses: Multiple additional covered indications include penile cancer (combination or maintenance), mycosis fungoides/Sezary syndrome, ASPS with axitinib, thymic carcinoma (non-thymoma), metastatic thyroid cancer with lenvatinib, uterine/vulvar/vaginal cancers with PD-L1/CPS criteria, various lymphomas and sarcomas as listed.
    Prior Authorization

    Keytruda Qlex prior authorization and step therapy

    When Keytruda Qlex is being requested, prior authorization applies and the benefit plan may impose step therapy requiring trial of preferred agent(s) before approving Keytruda Qlex.

    Step Therapy

    Preferred-agent trial may be required before Keytruda Qlex

    Approval of Keytruda Qlex may require documented trial of a preferred pembrolizumab product unless an exception applies; preferred agents are those deemed clinically comparable and preferred for clinical evidence and cost-effectiveness.

    • Preferred products list referenced in policy.
    • Exception allowed if patient is unable to use IV Keytruda due to no venous access.
    Billing Rule

    Benefit and prior authorization status varies by plan

    Benefit designation and prior authorization status differ by plan and effective dates: Keytruda is listed as Preferred and Keytruda Qlex as Non-Preferred on the specified Commercial, Medicaid, and Medicare effective dates.

    Prior Authorization

    Document prior therapy sequencing

    For certain indications, pembrolizumab use is contingent on prior therapies; documentation must show progression on or intolerance to specified prior systemic therapies before pembrolizumab is authorized.

    Step Therapy

    NSCLC: platinum progression/intolerance and targeted therapy sequencing

    For NSCLC single-agent indications (TPS ≥1% after platinum chemotherapy), prior progression on or intolerance to platinum-containing chemotherapy must be documented; patients with EGFR/ALK aberrations must have progressed on approved targeted therapy first.

    Step Therapy

    Follow indication-specific sequencing and prior therapy rules

    Some indications specify prior lines of therapy (for example: subsequent therapy in dMMR/MSI-H colorectal cancer after oxaliplatin/irinotecan/fluoropyrimidine), and prior exposure to nivolumab or pembrolizumab may preclude approval unless allowed by the indication.

    Step Therapy

    Approval if IV Keytruda cannot be used (no venous access)

    Keytruda Qlex may be approved if the individual is unable to use intravenous Keytruda due to lack of venous access; documentation of inability to use IV Keytruda is required to support approval.

    • Document inability to use IV administration (e.g., no venous access).
    • Specify requested Keytruda Qlex vial strength and dosing interval per quantity limits.
    Step Therapy

    Keytruda Qlex requires preferred-agent trial unless IV contraindicated

    Keytruda Qlex is subject to step therapy: approval generally requires prior use of a preferred agent unless the patient is unable to use IV Keytruda (documented no venous access).

    Note

    Plan utilization management may take precedence

    Plan-level utilization management programs or other plan policies may impose step therapy or other requirements that take precedence over the clinical criteria in this policy.

    Documentation Required

    Provide PD-L1 / MSI / TMB biomarker results when required

    Where an FDA indication or NCCN recommendation requires biomarkers, documentation of tumor PD-L1 status (e.g., CPS or TPS), MSI/MMR, or TMB results must be provided with the prior authorization request.

    Documentation Required

    Include specific biomarker details (TPS, EGFR/ALK, MSI/dMMR, TMB)

    Required biomarker documentation should include PD-L1 TPS where relevant, EGFR/ALK genomic status for NSCLC, and MSI-H/dMMR or TMB-H status (TMB ≥10 mut/Mb) when claiming biomarker-based indications.

    Documentation Required

    Submit diagnosis, prior therapies, biomarkers, and performance status

    Clinical documentation must include diagnosis, line of therapy, prior therapies, relevant biomarker status (dMMR/MSI-H, PD-L1 CPS/TPS, TMB, POLE/POLD1 where relevant), ECOG performance status, and whether prior anti–PD-1/PD-L1 therapy was given.

    Documentation Required

    Show patient meets indication-specific clinical thresholds

    Documentation provided with the request must demonstrate the patient meets the indication-specific criteria described in the policy, including ECOG or Karnofsky performance thresholds and other case-specific requirements.

    Documentation Required

    Document inability to use IV Keytruda and requested Qlex dosing

    For Keytruda Qlex requests, include documentation supporting inability to use IV Keytruda (for example, no venous access) and indicate the requested Keytruda Qlex vial strength and dosing interval per stated quantity limits.

    • State evidence of no venous access.
    • Specify 395 mg per 21 days or 790 mg per 42 days vial strength requested as applicable.
    Note

    Use cited literature and package inserts to support requests

    References cited in the policy—such as package inserts, KEYNOTE trials, and NCCN guidelines—may be used to support the clinical rationale provided with prior authorization requests.

    Denial Risk

    Requests outside labeled or compendia uses may be denied

    Requests for use that do not match FDA-labeled indications or NCCN compendia uses outlined in this document may be denied for lack of documented indication.

    Denial Risk

    PMBCL with urgent cytoreductive need may be denied

    Keytruda is not recommended for PMBCL patients who require urgent cytoreductive therapy; such cases may be denied if urgent cytoreduction is clinically required.

    Denial Risk

    Performance status and prior anti–PD-1/PD-L1 therapy considerations

    Most indications require ECOG performance status 0–2 (some allow 0–3); requests where the beneficiary's performance status is outside the referenced ranges or where prior anti–PD-1/PD-L1 therapy contradicts the indication may be denied.

    Denial Risk

    Concurrent systemic immunosuppression exclusion

    Use in patients receiving systemic immunosuppressant therapy or active autoimmune disease therapy is excluded in many indications and may trigger denial of the request.

    Denial Risk

    Denial triggers for unmet criteria or missing documentation

    Requests that do not meet the specified indication criteria (including PMBCL requiring urgent cytoreductive therapy) or lack required documentation may not be approved.

    Denial Risk

    Keytruda Qlex may be denied if IV Keytruda is feasible

    If the individual can use IV Keytruda, requests for Keytruda Qlex may be denied—an exception applies only when inability to use IV Keytruda (e.g., no venous access) is documented.

    Note

    Legal/contractual and plan UM precedence

    Federal or state laws, contract language, and Plan utilization management programs or policies may take precedence over this clinical criteria and affect authorization decisions.

    Regulatory contextThe FDA granted tumor-agnostic approval for pembrolizumab in solid tumors with TMB-H (≥10 mut/Mb) after progression following prior treatment and no satisfactory alternatives.
    Clinical guidanceNCCN provides additional recommendations for select tumor types (e.g., small bowel, colorectal, ovarian) referencing TMB-H in certain first-line or subsequent settings.
    Tumor Mutational Burden (TMB) numeric threshold
    Numeric thresholdTMB‑High (TMB‑H) defined as ≥10 mutations per megabase (mut/Mb).
    Ultra‑hypermutated notePolicy also notes ultra‑hypermutated phenotypes (examples: TMB >50 mut/Mb) in select contexts such as POLE/POLD1‑mutated tumors.
    Test requirementTMB must be determined by an FDA‑approved test to support the labeled tumor‑agnostic indication.
    PD-L1 Tumor Proportion Score (TPS) thresholds
    TPS ≥50%PD‑L1 Tumor Proportion Score (TPS) ≥50% — required for first‑line single‑agent pembrolizumab in metastatic NSCLC (no EGFR/ALK aberrations).
    TPS ≥1%PD‑L1 TPS ≥1% — used for other NSCLC indications such as subsequent‑line single‑agent therapy after platinum chemotherapy and certain stage III/IV settings per label.
    Genomic contextFor TPS‑based indications, absence of actionable EGFR/ALK genomic aberrations or prior progression on targeted therapy is often required per NSCLC criteria.
    PD-L1 CPS thresholds by indication
    CPS ≥10PD‑L1 CPS ≥10 — required for pembrolizumab in TNBC (locally recurrent, unresectable, or metastatic) and for certain esophageal squamous cell carcinoma single‑agent indications after prior therapy.
    CPS ≥1PD‑L1 CPS ≥1 — threshold used for gastric/GEJ adenocarcinoma, cervical cancer, vulvar cancer, and some first‑line palliative combinations per FDA/NCCN guidance.
    Indication variabilityThe policy specifies CPS thresholds vary by tumor type and indication (examples CPS ≥1 or CPS ≥10 depending on label/NCCN recommendation).
    TMB high (contextual)
    TMB‑H primary thresholdTMB‑High commonly referenced as ≥10 mut/Mb for tumor‑agnostic FDA indication and many policy entries.
    Ultra‑hypermutated phenotypePolicy notes ultra‑hypermutated phenotypes (e.g., TMB >50 mut/Mb) as context for POLE/POLD1‑mutated colorectal or small bowel tumors.
    Use conditionsTMB‑H use is described for unresectable/metastatic solid tumors after prior therapy and when no satisfactory alternatives exist; Karnofsky ≥70% often required for tumor‑agnostic use.
    Tumor mutation burden (TMB) numeric entry
    Numeric entryTumor Mutational Burden (TMB) numeric threshold used in this policy: ≥10 mutations per megabase (mut/Mb).
    Regulatory noteFDA‑approved tests determining ≥10 mut/Mb are referenced for the tumor‑agnostic pembrolizumab indication.
    DocumentationPrior authorization should confirm TMB result and test method when claiming a TMB‑H indication per required biomarker documentation guidance.
    PD-L1 / CPS thresholds (various contexts)
    PD‑L1 ≥1% contextsPD‑L1 expression ≥1% is used for several NSCLC indications (e.g., subsequent‑line monotherapy, some first‑line stage III/IV settings) and for brain metastases scenarios noted in NSCLC entries.
    PD‑L1 ≥50% monotherapyPD‑L1 ≥50% (TPS) is required for first‑line single‑agent pembrolizumab in metastatic NSCLC without actionable genomic aberrations.
    CPS vs TPSThe policy differentiates scoring methods: CPS is used widely across gastrointestinal, gynecologic and head & neck cancers; TPS is used primarily in NSCLC contexts.
    Keytruda Qlex vial quantity limits
    Vial strengths and intervalKeytruda Qlex vial quantity limits: 395 mg (4,800 units) — 1 vial (2.4 mL) per 21 days; 790 mg (9,600 units) — 1 vial (4.8 mL) per 42 days.
    Step therapy relationRequested vial strength and dosing interval should match the quantity limits when submitting prior authorization for Keytruda Qlex.
    Coding and operational noteQuantity limits were added as a material update in document history and tie to HCPCS coding changes for Keytruda Qlex in the policy history.
    MSI‑H/dMMR is referenced for colorectal, endometrial, small bowel, gastric/esophagogastric, biliary tract and other solid tumors in the policy.
    Line of therapyMSI‑H/dMMR indications include first‑line single‑agent use in some settings and subsequent‑line use after prior systemic therapy per label/NCCN guidance.
    TMB-H numeric threshold
    Numeric thresholdTMB‑High numeric threshold specified in policy: ≥10 mutations per megabase (mut/Mb).
    FDA test requirementTMB must be measured by an FDA‑approved test to support the tumor‑agnostic indication for pembrolizumab.
    Clinical notePolicy references TMB‑H both as ≥10 mut/Mb and notes ultra‑hypermutated examples (>50 mut/Mb) in select POLE/POLD1 contexts.
    PD-L1 (TPS) thresholds
    TPS ≥50%Tumor Proportion Score (TPS) ≥50% — required for first‑line single‑agent pembrolizumab in metastatic NSCLC without EGFR/ALK aberrations.
    TPS ≥1%TPS ≥1% — used for other NSCLC indications including subsequent‑line single‑agent treatment after platinum chemotherapy and certain stage III/IV settings.
    Testing and sequencingPD‑L1 TPS results and absence of actionable genomic markers (or progression on targeted therapy) should be documented for TPS‑based NSCLC indications.
    Tumor Mutational Burden (TMB) — numeric
    Numeric thresholdTumor Mutational Burden (TMB) numeric threshold in policy: ≥10 mutations per megabase (mut/Mb) for TMB‑H designation.
    Tumor‑agnostic usePolicy cites FDA tumor‑agnostic approval for TMB‑H solid tumors (≥10 mut/Mb) after progression on prior therapy and no satisfactory alternatives.
    Ultra‑hypermutated exceptionSelect cases with POLE/POLD1 mutations may show ultra‑hypermutated phenotype (e.g., >50 mut/Mb) noted separately in the policy.
    MSI-H / dMMR (alternate entry)
    MSI‑H / dMMR positive presencePolicy requires MSI‑H or dMMR positive status (present/yes) for multiple tumor‑agnostic and tumor‑specific indications; numeric threshold not applicable — presence is sufficient.
    Indication examplesColorectal, small bowel, endometrial and other solid tumors are listed where MSI‑H/dMMR positivity qualifies patients for pembrolizumab in first‑line or subsequent settings.
    DocumentationPrior authorization must include test results demonstrating MSI‑H/dMMR when claiming these biomarker‑driven indications.
    dMMR / MSI-H (positive presence)
    Positive presencedMMR / MSI‑H positive status (present) is an eligibility requirement for numerous pembrolizumab indications per FDA/NCCN guidance.
    No numeric thresholdMSI‑H/dMMR is represented as a positive biomarker state rather than a numeric cutoff; testing method and result must be documented.
    Applies across tumorsUsed in colorectal, small bowel, endometrial, gastric/esophageal and tumor‑agnostic indications listed in the policy.
    PD-L1 (CPS) thresholds by indication
    CPS ≥10PD‑L1 CPS ≥10 — used for specific indications such as esophageal squamous cell carcinoma (recurrent/metastatic) and TNBC per FDA labeling; cited repeatedly in indication sections.
    CPS ≥1PD‑L1 CPS ≥1 — used for gastric/GEJ adenocarcinoma, cervical cancer, vulvar cancer and other indications per policy examples.
    Indication‑specific usePolicy lists CPS thresholds by tumor type and by line of therapy — providers must document CPS results consistent with the relevant indication.
    TMB — ultra-hypermutated phenotype (>50 mut/Mb) note
    Ultra‑hypermutated phenotypePolicy notes ultra‑hypermutated phenotype examples with TMB >50 mut/Mb (e.g., POLE/POLD1 mutated tumors) as a distinct context from standard TMB‑H definitions.
    Clinical relevanceUltra‑hypermutated tumors may be identified by POLE/POLD1 mutations and may guide single‑agent pembrolizumab use in selected colorectal/small bowel contexts per NCCN 2A recommendations.
    Complement to TMB‑HThis note complements the primary TMB‑H threshold (≥10 mut/Mb) by highlighting rare, very high mutation‑burden phenotypes used in specific indications.
    POLE/POLD1 mutation — ultra-hypermutated example
    POLE/POLD1 examplePOLE/POLD1 mutations are cited as examples associated with an ultra‑hypermutated phenotype (example: TMB >50 mut/Mb) relevant for colorectal and small bowel indications.
    Indication linkageWhen POLE/POLD1 mutation leads to ultra‑hypermutated phenotype, pembrolizumab monotherapy may be considered for advanced colorectal or small bowel adenocarcinoma per policy criteria.
    DocumentationMutation status and supporting TMB results should be included in prior authorization documentation where applicable.
    PD-L1 threshold (various contexts)
    TPS ≥50% (NSCLC)PD‑L1 TPS ≥50% is specified for first‑line single‑agent metastatic NSCLC without EGFR/ALK aberrations — documented TPS required.
    CPS/TPS cross‑referencesPolicy lists both CPS and TPS thresholds depending on tumor type; providers must use the appropriate scoring method for the indication.
    Lower TPS thresholdsPD‑L1 TPS ≥1% is used for other NSCLC settings including subsequent‑line therapy and some stage III/IV indications per label/NCCN.
    Tumor mutation burden (TMB) numeric entry
    TMB numeric entryTumor mutation burden (TMB) numeric threshold used in policy entries: ≥10 mutations per megabase (mut/Mb).
    Test specificationTMB must be determined by an FDA‑approved assay to support the labeled tumor‑agnostic pembrolizumab indication.
    Ultra‑hypermutated mentionPolicy also references ultra‑hypermutated examples (e.g., >50 mut/Mb) in select contexts such as POLE/POLD1 mutations.
    dMMR / MSI-H presence (duplicate emphasis)
    dMMR/MSI‑H presencePolicy consistently treats dMMR or MSI‑H as a positive biomarker state (presence/yes) required for many tumor‑agnostic and tumor‑specific indications.
    No numeric cutoffUnlike TMB, MSI‑H/dMMR is not a numeric threshold but a categorical test result that must be documented to support eligibility.
    Applies broadlyMSI‑H/dMMR is used across colorectal, small bowel, endometrial, gastric/esophageal and other tumor indications in the policy.
    PD-L1 (CPS or TPS) thresholds — CPS ≥10; TPS ≥1%
    CPS ≥10 and TPS ≥1% examplesPolicy highlights commonly referenced thresholds together: PD‑L1 CPS ≥10 for some gastroesophageal and TNBC indications; PD‑L1 TPS ≥1% for some NSCLC settings — the policy elsewhere summarizes CPS ≥10 and TPS ≥1% as key actionable cutoffs.
    Documentation needPrior authorization must include the appropriate PD‑L1 test result (CPS or TPS) matching the indication's required scoring method and cutoff.
    Indication specificityThe policy emphasizes that CPS vs TPS and the numeric cutoff are indication‑specific and must be applied per FDA label or NCCN guidance.
    MSI-H / dMMR (document history reference)
    Document historyPolicy history documents the addition of TMB‑H and MSI‑H/dMMR indications and multiple updates; these entries provide provenance for threshold choices (e.g., TMB ≥10 mut/Mb).
    Coding updatesDocument history includes coding updates and operational changes that relate to Keytruda Qlex and quantity limits added in recent revisions.
    Reference listingReferences (KEYNOTE studies, NCCN guidelines, DailyMed package inserts) cited in the history support biomarker thresholds and indication expansions.
    Tumor mutational burden (TMB) (document history reference)
    TMB policy provenanceThe policy records the FDA tumor‑agnostic approval for TMB‑H (≥10 mut/Mb) and cites KEYNOTE‑158 and related references in the document history and references section.
    Clinical referencesKEYNOTE studies and NCCN guidance are cited as supporting literature for TMB‑H use and thresholds in the policy references list.
    Operational notePrior authorization processes require TMB documentation and test method when claiming TMB‑H eligibility per policy guidance.
    DefinitionPD‑L1 Combined Positive Score (CPS) — a tumor PD‑L1 expression scoring method used to determine eligibility for several pembrolizumab indications (policy examples include CPS ≥1 and CPS ≥10).
    Scoring useCPS is applied across multiple tumor types (gastrointestinal, gynecologic, head & neck, and others) where PD‑L1 expression determines pembrolizumab eligibility.
    DocumentationAn FDA‑approved test result for CPS must be provided in prior authorization where CPS‑based eligibility is claimed.
    Classical Hodgkin lymphoma (cHL) definition reference
    DefinitionClassical Hodgkin lymphoma (cHL) — a lymphoid malignancy distinguished by Reed‑Sternberg cells; pembrolizumab is FDA indicated for relapsed or refractory cHL in adults and pediatrics in specified settings.
    Indication notePolicy lists FDA indication for relapsed/refractory cHL and cites NCCN compendia recommending pembrolizumab as therapy option in relapsed/refractory settings.
    Prior therapy contextUse typically follows prior lines of therapy; documentation of prior treatments and eligibility per label is required for authorization.
    TMB-H
    TMB‑H definitionTMB‑High (TMB‑H) in this policy is defined as ≥10 mutations per megabase (mut/Mb) as determined by an FDA‑approved test for the tumor‑agnostic pembrolizumab indication.
    ApplicationTMB‑H is used to qualify unresectable or metastatic solid tumors for pembrolizumab when prior therapy has failed and no satisfactory alternatives exist.
    Supporting evidenceKEYNOTE‑158 and related references are cited in the policy references supporting TMB‑H clinical rationale.
    dMMR/MSI-H/TMBH combined definition note
    Combined biomarker notePolicy groups dMMR/MSI‑H/TMB‑H as actionable biomarker states used for tumor‑agnostic or tumor‑specific pembrolizumab indications; each biomarker has distinct testing and threshold semantics (dMMR/MSI‑H = presence; TMB‑H = ≥10 mut/Mb).
    Coverage contextsThese biomarkers are referenced across colorectal, small bowel, endometrial, gastric, biliary tract and other solid tumor indications in the policy.
    Documentation requirementTest results for dMMR/MSI‑H or TMB must be included in prior authorization when claiming biomarker‑driven eligibility.
    PD-L1 CPS definition (threshold examples)
    CPS thresholdsPD‑L1 CPS thresholds used in the policy include CPS ≥1 and CPS ≥10 depending on indication; CPS ≥10 is required for selected esophageal and TNBC uses, CPS ≥1 for gastric/GEJ, cervical and vulvar uses.
    CPS examplesPolicy examples explicitly cite CPS ≥1 and CPS ≥10 as the most common actionable cutoffs across tumor types.
    Scoring distinctionPolicy emphasizes use of CPS for many GI and gynecologic tumors while TPS is used primarily for NSCLC.
    Actionable molecular markers list (testing recommended)
    Actionable molecular markersActionable molecular markers listed include EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, NRG1, and ERBB2 (HER2); NCCN recommends testing prior to initiating therapy to guide treatment decisions.
    Testing guidanceIf insufficient tissue exists for testing, repeat biopsy or plasma testing is recommended; if unknown, patients are treated as though driver‑negative per NCCN guidance cited in the policy.
    NSCLC relevanceAbsence of actionable markers (or prior progression on targeted therapy) is often required for PD‑1 monotherapy NSCLC indications (TPS‑based).
    BCG-unresponsive definition
    BCG‑unresponsive definitionBCG‑unresponsive disease is defined as: persistent disease despite adequate BCG (≥5 induction doses plus ≥2 maintenance OR ≥2 second induction doses), recurrence after an initial tumor‑free state following adequate BCG, or T1 disease following a single induction course.
    Eligibility contextPolicy requires BCG‑unresponsive definition plus ineligibility for cystectomy and absence of prior anti‑PD‑1/PD‑L1 therapy for coverage in high‑risk non‑muscle invasive bladder cancer settings.
    Performance and immunosuppressionECOG 0‑2 and no systemic immunosuppressant therapy are required per the policy for BCG‑unresponsive coverage entries.
    Preferred (definition for step therapy context)
    Preferred definitionPreferred refers to agents deemed clinically comparable within class or disease category but chosen based on clinical evidence and cost‑effectiveness; used in step therapy logic for Keytruda Qlex.
    Step therapy implicationWhen Keytruda Qlex is subject to step therapy, plan may require trial of a preferred agent unless exception (e.g., no venous access) is documented.
    Operational useThe policy's prior authorization and plan benefit status sections reference preferred status when determining step therapy requirements for Keytruda Qlex.
    Keytruda Qlex naming entry (document title reference)
    Naming and contentsKeytruda Qlex is the policy name for the subcutaneous combination product containing pembrolizumab and berahyaluronidase alfa‑pmph; NCCN notes Keytruda Qlex may be substituted for IV pembrolizumab.
    Regulatory listingThe policy overview lists Keytruda Qlex FDA‑labeled disease states and documents that Keytruda Qlex enables SC administration of pembrolizumab.
    Operational notesStep therapy, quantity limits, and coding updates specific to Keytruda Qlex are recorded in the document history and operational sections of the policy.
    2022-11-18regimen_addition

    Added criteria for pembrolizumab in combination with lenvatinib for advanced endometrial carcinoma (pMMR) per FDA label and combination use with Inlyta (axitinib) in select sarcoma indications—recorded in the document history.

    2024-11-15regimen_addition

    Added FDA indication for malignant pleural mesothelioma in combination with pemetrexed and platinum as first-line therapy; coding updates reflected in document history.

    Document history entry notes removal of the small cell lung cancer (SCLC) indication following FDA withdrawal; reviewers should reference the policy history for prior timeline details and prior-coded changes related to SCLC.